Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene - a gene that can cause cancer - that ...

Researchers have identified a mutation in a common oncogene that may play an important role in colon cancer. Their findings ...

Verastem shows strong late-stage pipeline progress, financial discipline, and a diverse portfolio that support long-term ...

One mutation, called KRAS G12V, stood out from the others. All three mutations are involved in creating a molecule called acetyl-CoA, an important building block for fatty acids and proteins.

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with ...

An RNA interference (RNAi) molecule that selectively targets the KRAS G12V mutation could represent a key advance in the ...

The research, published August 29 in Cancer Cell, demonstrates that KRAS mutations, which occur in about 95 percent of people who have PDAC, can vary, with KRAS-G12R, KRAS-G12D and KRAS-G12V being ...

The KRAS G12C mutation is found in approximately 3% of all colorectal cancer cases and 1% to 2% of pancreatic adenocarcinoma cases, according to Xie. KRAS G12C inhibitors like sotorasib (Lumakras) and ...

The Food and Drug Administration (FDA) has granted accelerated approval to Avmapki ™ (avutometinib) plus Fakzynja ™ (defactinib) for the treatment of adult patients with KRAS- ...

In June 2025, AstraZeneca announced a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line ...

The research, published August 29 in Cancer Cell, demonstrates that KRAS mutations, which occur in about 95% of people who have PDAC, can vary, with KRAS-G12R, KRAS-G12D and KRAS-G12V being the ...